The present invention is based on our work with E-cadherin containing the soluble portion of this essential membrane glycoprotein. The composition of the invention comprises a first agent that targets an epitope within one or more EC2-EC5 subdomains of an E-cadherin ectodomain (including a domain in a shed sEcad fragment), and endothelial tube formation； Angiogenesis, human epidermal growth factor receptor family (i.e., HER1-4), insulin-like growth factor 1 receptor (IGF-1R), tyrosine kinase receptor family members of any other receptor, the P13K-MAPK pathway, and A therapeutically effective amount of a second agent that inhibits one or more of the P13K / Akt / mTOR pathways is included. The composition can be used in the treatment of epithelial cancer and can efficiently inhibit cell proliferation, migration, and / or invasiveness. Thus, the compositions of the present invention can be used to inhibit tumor growth and metastasis. The compositions of the invention are used in the treatment of "triple negative" breast cancer patients (negative in breast cancer cell tests for estrogen receptor, progesterone receptor, and HER2), as well as HER2-positive and other HER2-negative tumors be able to. In addition to therapeutic and prophylactic treatments, the present invention relates to cancer in response to the relative amounts of full-length (FL) E-cadherin and soluble E-cadherin (sEcad) and / or with other predictive biomarkers for cancer. Featuring a grading method. The greater the amount of sEcad relative to the amount of FL E-cadherin, the more advanced the cancer. [Selection figure] None本発明は、この必須膜糖タンパク質の可溶性部分を含むE-カドヘリンを用いた、本発明者らの研究に基づく。本発明の組成物は、(shed sEcad断片中のドメインを含めた)E-カドヘリンエクトドメインの1個以上のEC2～EC5サブドメイン内部のエピトープを標的化する第1作用物質、及び内皮管形成、血管新生、ヒト上皮増殖因子受容体ファミリー(即ちHER1～4)、インスリン様増殖因子1受容体(IGF-1R)、任意の他の受容体のチロシンキナーゼ受容体ファミリーメンバー、P13K-MAPK経路、及びP13K/Akt/mTOR経路の1個以上を阻害する第2作用物質を治療有効量含む。組成物は上皮癌の治療において使用することができ、細胞の増殖、移動、及び/又は浸潤性を効率よく阻害することができる。したがって、本発明の組成物を使用して腫瘍の増殖及び転移を阻害することができる。本発明の組成
